Hexarelin vs GHRP-6: GH, Tolerance & Human Evidence

At a Glance: Side-by-Side Comparison

GH Secretion: Read the Exposure and Endpoint

Both peptides stimulate GH in human experiments, but the reviewed studies do not support universal peaks of 15-20 times baseline for hexarelin versus 10-15 times for GHRP-6. A ratio to baseline depends on the starting level, sampling, exposure and assay; it is not a fixed potency score.

In six healthy young men, a one-day study of subcutaneous hexarelin increased GH secretory pulse mass without increasing pulse frequency. Two and three administrations produced similar overall GH increases. This is evidence of biological activity, not proof that an extra daily dose improves muscle growth. 2002 one-day hexarelin study

GHRP-6 also increased GH pulse amplitude without increasing pulse frequency in the separate 34-hour intravenous infusion study. That observation does not establish a lower but more sustainable effect than hexarelin, because the experiments did not compare the two treatments under matched conditions. 1993 GHRP-6 infusion study

Tolerance: Partial Attenuation Is Not Complete Loss of Effect

In 12 healthy older people receiving subcutaneous hexarelin twice daily for 16 weeks, the GH response became smaller but did not disappear. Four weeks after treatment ended, the response was no longer significantly different from the starting response. This is encouraging evidence of partial, reversible attenuation under that study schedule, not proof that everyone needs the same on/off cycle. 1998 hexarelin attenuation report

A smaller response to a fresh dose can coexist with increased overall secretion. In nine healthy young men, a 34-hour intravenous GHRP-6 infusion increased integrated GH, pulse amplitude and IGF-I while reducing the response to an additional bolus. That does not establish indefinite effectiveness or a superior long-term tolerance profile compared with hexarelin. 1993 GHRP-6 infusion study

These experiments used different populations, administration patterns and observation periods. They cannot establish that one peptide permanently desensitizes receptors while the other avoids the problem. User reports of changing effects can be described as experiences, but are not a measurement of receptor recovery.

Appetite: A Measured Signal, Not a Universal Ranking

A human hexarelin experiment involving 15 healthy young men found a small acute increase in appetite ratings during test sessions that monitored hormones for two hours after injection. This supports an appetite signal, but the rating scale did not measure calories eaten or subsequent weight gain. It was not a comparison with GHRP-6. 1999 hexarelin appetite and endocrine study

Users often describe increased hunger after GHRP-6. Those reports can be useful context without establishing that everyone experiences an immediate, uncontrollable urge to eat. Comparing a personal report with a rating from a separate hexarelin experiment cannot establish which peptide reliably causes more hunger.

GHRH Combinations: Correct the Classification First

Ipamorelin is a growth hormone secretagogue, not a GHRH analog. Its original pharmacology work used pituitary cells, rats and swine and found a GHRP-like receptor mechanism. It should not be grouped with GHRH analogs as though they act at the same receptor, and its animal selectivity findings do not establish the safety of a human combination. 1998 ipamorelin pharmacology study

Acute human combination evidence exists. An intravenous dose-response experiment in healthy adult men found that low-dose hexarelin and GHRH acted synergistically on GH release; prolactin also rose, while cortisol did not rise under that combination condition. This does not establish the same profile at other exposures or with CJC-1295. 1996 hexarelin/GHRH dose-response study

In separate intravenous challenge sessions, 11 controls showed a GHRP-6/GHRH GH response over two hours greater than the sum of the separate responses, whereas 12 patients with hypothalamopituitary disconnection did not show the same synergy. A positive acute endocrine interaction is not a trial of long-term bodybuilding benefit or proof that mixing products in one syringe is appropriate. 1995 GHRP-6/GHRH study

Cycling: Research Observations Versus a Treatment Schedule

Recovery observed four weeks after the hexarelin study ended does not validate a universal six-week-on/four-week-off cycle. The short GHRP-6 infusion likewise cannot establish that weekend breaks, rotating peptides or year-round use preserves responsiveness. Study schedules should remain attached to their studies, not become general prescriptions.

Commonly circulated injection and combination schedules are not validated by the evidence reviewed here for muscle gain or fat loss. Route, preparation, clinical purpose and monitoring cannot be inferred from the fact that an experimental dose raised GH.

Hormone Effects Depend on the Study and Schedule

Hexarelin should not be labeled prolactin-neutral. In seven young adult volunteers, intravenous hexarelin, GHRP-2 and Tyr-Ala-hexarelin stimulated prolactin, ACTH and cortisol as well as GH. GHRP-6 was not an administered comparator, so this experiment does not establish a side-effect ranking between the two peptides discussed here. 1999 acute endocrine study

Repeated-exposure findings are more nuanced. A 16-week subcutaneous hexarelin study found no significant change in the prolactin response or urinary free cortisol, while the acute cortisol response became smaller during treatment and recovered after treatment ended. Those findings are worth retaining, but they do not demonstrate that every formulation or long-term use is free of endocrine effects. 1999 chronic hexarelin endocrine study

In a separate one-day study of six healthy young men, two and three subcutaneous hexarelin administrations increased overall GH secretion similarly without changing IGF-I, prolactin, ACTH or cortisol. A subsequent intravenous challenge produced different hormonal responses. The route, timing and measured endpoint matter when interpreting apparently conflicting results. 2002 one-day hexarelin study

A hormone change in a small experiment is not a predictable side-effect rate for a person using a different preparation. The reviewed findings do not justify routinely adding a cortisol antagonist or another hormone-active medicine to manage presumed peptide effects.

Choosing by the Question the Evidence Can Answer

For a comparison of acute GH physiology, examine the actual challenge study. For appetite, distinguish a symptom rating from food consumed. For body composition, look for measurements of fat and lean mass rather than assuming that a GH rise proves either outcome. These are different questions, not interchangeable measures of success.

The reviewed evidence does not establish a best bulking peptide, a best cutting peptide or a proven benefit from taking hexarelin and GHRP-6 together. Reports of better recovery or easier eating can remain visible as anecdotes without becoming a ranked treatment recommendation.

A reliable monthly cost comparison requires a dated, comparable price source. Price comparisons would need the exact preparation, quantity and services included; a supplier price alone does not establish product suitability or clinical value.

Results: GH Changes Are Not a Body-Composition Timeline

In the 16-week subcutaneous hexarelin study, total body fat, lean body mass and bone mineral density did not change significantly from baseline. IGF-I and its binding protein also did not change significantly, although one bone-formation marker increased. The study demonstrated hormonal responsiveness and attenuation, not the predicted muscle definition or fat loss by weeks three to four. 1998 long-term hexarelin study

Better sleep is not an automatic consequence of a GH rise. In seven young healthy volunteers receiving repeated hexarelin or placebo overnight, GH increased but stage 4 sleep in the first half of the night and whole-night EEG delta power decreased. That small acute experiment does not establish every user's sleep response, but it contradicts a blanket promise of improved sleep. 2004 hexarelin sleep study

In normal male controls, repeated intravenous GHRP-6 boluses versus placebo increased stage 2 sleep without changing slow-wave sleep during overnight EEG recording. It is not a concurrent comparison with hexarelin and does not prove better day-to-day sleep quality, training recovery or a predictable results timeline. 1995 GHRP-6 sleep study